JB

Jamil Beg

Venture Capitalist & Bioentrepreneur

Cambridge, Massachusetts

Overview 

Jamil Beg is a Venture Capitalist and Bioentrepreneur based in Cambridge, Massachusetts, currently serving as a Partner at SV Health Investors. With a background in biotechnology and pharmaceuticals, he has been a founding investor and CEO at Renasant Bio, Nido Biosciences, and Kinaset Therapeutics, and has made significant investments in companies like Kinaset Therapeutics at the Series A stage. Highlights of his career include founding and leading multiple successful biotech startups and serving as a Partner at 5AM Ventures, showcasing his expertise in strategic investments and leadership within the life sciences industry.

Work Experience 

  • Partner

    2024 - Current

SV Health Investors is a boston-based venture capital firm focused on investments in biotechnology and healthcare industry.

  • Founding Investor

    2020

    Clinical stage, small molecule company developing inhaled therapeutics for respiratory diseases

  • Board of Directors

    2020

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Raised $41,500,000.00 from Gimv, Atlas Venture and 5AM Ventures.

  • Founding Investor

    2022

    Stealth stage genetic renal disease company

  • Chief Executive Officer

    2022 - 2023

  • Founder

    2018

    Clinical stage, precision neuroscience company developing small molecules to transform the lives of patients suffering from neurological diseases

  • Board of Directors

    2018 - 2023

  • Chief Executive Officer

    2018 - 2021

Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.

Raised $109,000,000.00 from Bioluminescence Ventures.

  • Partner

    2017 - 2023

    5AM Ventures is an early stage life science venture fund focused on company creation and investments in seed and Series A companies

5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.

  • Guest Lecturer

    2019 - 2022

  • Board Observer

    2018 - 2021

    Clinical stage company developing transformative breakthrough therapies for patients with severe and rare disorders (IPO in July 2021)

Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.

Raised $238,600,000.00 from Johnson & Johnson Innovation – JJDC.

  • Board Member

    2007 - 2021

BioBreak is a members-only community fostering connections among life sciences executives and investors.

  • Mentor

    2017 - 2021

  • Board Observer

    2017 - 2020

    Clinical stage, gene therapy company developing treatments for inner ear disorders (IPO in June 2020; acquired by Eli Lilly in October 2022)

Akouos is a biotechnology company focusing on restoring and preserving hearing.

Raised $162,500,000.00 from Fidelity, PAG, New Enterprise Associates, Polaris Founders Capital, Novartis Venture Fund, Cormorant Asset Management, Pivotal bioVenture Partners, RA Capital Management, Surveyor Capital and Wu Capital.

Articles About Jamil

Relevant Websites